CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. Show more

Location: 835 Industrial Road, San Carlos, CA, 94070, United States | Website: https://cargo-tx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

193.2M

52 Wk Range

$3.00 - $25.45

Previous Close

$4.19

Open

$4.18

Volume

218,590

Day Range

$4.11 - $4.22

Enterprise Value

-95.18M

Cash

318.8M

Avg Qtr Burn

-36.82M

Insider Ownership

0.66%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date